Trials / Completed
CompletedNCT05810948
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of efgartigimod IV in Chinese patients with active lupus nephritis (LN). The study comprises an approximate 4-week screening period, a 24-week treatment period, and an 8-week follow- up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | efgartigimod IV | Intravenous (IV) infusion of efgartigimod |
| OTHER | Placebo | Intravenous (IV) infusion of placebo |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2025-07-02
- Completion
- 2025-09-01
- First posted
- 2023-04-13
- Last updated
- 2025-12-18
Locations
31 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05810948. Inclusion in this directory is not an endorsement.